
    
      The investigators are trying to establish that routine clinical practice for voriconazole
      therapeutic drug monitoring can improve the efficacy and safety outcomes.

      In Korean patients with hematologic malignancy, the investigators also want to propose the
      optimal dosing guideline of voriconazole with different genetic polymorphisms.
    
  